| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Impact of EGFR expression on colorectal cancer patient prognosis and survival.
|
Ann Oncol
|
2005
|
3.34
|
|
2
|
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
|
Br J Cancer
|
2006
|
2.75
|
|
3
|
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
|
Ann Oncol
|
2013
|
2.66
|
|
4
|
WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type.
|
Oncogene
|
2001
|
2.32
|
|
5
|
Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer.
|
Br J Cancer
|
2002
|
1.76
|
|
6
|
Interleukin-6 overexpression as a marker of malignancy in human gliomas.
|
J Neurosurg
|
2001
|
1.57
|
|
7
|
[Mixed müllerian tumours of the endometrium. About four cases developed on tamoxifen treatment].
|
Gynecol Obstet Fertil
|
2003
|
1.40
|
|
8
|
[Is there still a place for extemporaneous exam in breast cancer?].
|
Gynecol Obstet Fertil
|
2006
|
1.37
|
|
9
|
Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study.
|
Histopathology
|
2003
|
1.23
|
|
10
|
Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases.
|
Crit Rev Oncol Hematol
|
2009
|
1.18
|
|
11
|
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.
|
Br J Cancer
|
2003
|
1.17
|
|
12
|
Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies.
|
Endocr Relat Cancer
|
2009
|
1.16
|
|
13
|
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.
|
Ann Oncol
|
2012
|
1.14
|
|
14
|
Expression of the FGFR1 gene in human breast-carcinoma cells.
|
Int J Cancer
|
1994
|
1.11
|
|
15
|
p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results.
|
Br J Cancer
|
1994
|
1.07
|
|
16
|
Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer.
|
Ann Oncol
|
2007
|
1.07
|
|
17
|
Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.
|
Gynecol Oncol
|
2000
|
1.04
|
|
18
|
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts.
|
Ann Oncol
|
2009
|
0.99
|
|
19
|
Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma.
|
Biochem Biophys Res Commun
|
2005
|
0.99
|
|
20
|
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes.
|
Ann Oncol
|
2008
|
0.98
|
|
21
|
Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?
|
Br J Cancer
|
2003
|
0.97
|
|
22
|
Personalized cancer medicine and the future of pathology.
|
Virchows Arch
|
2011
|
0.97
|
|
23
|
Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience.
|
Br J Cancer
|
2009
|
0.93
|
|
24
|
Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue.
|
Histopathology
|
2008
|
0.92
|
|
25
|
O(6)-methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation.
|
Int J Cancer
|
1999
|
0.91
|
|
26
|
DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection.
|
Mol Hum Reprod
|
2004
|
0.90
|
|
27
|
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.
|
Ann Oncol
|
2012
|
0.90
|
|
28
|
Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients.
|
Eur J Cancer
|
2001
|
0.89
|
|
29
|
Ovarian epithelial dysplasia after ovulation induction: time and dose effects.
|
Hum Reprod
|
2008
|
0.89
|
|
30
|
Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study.
|
Ann Oncol
|
2014
|
0.88
|
|
31
|
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.
|
Br J Cancer
|
2010
|
0.88
|
|
32
|
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate.
|
Br J Cancer
|
2003
|
0.88
|
|
33
|
Zinc-alpha2-glycoprotein: a new biomarker of breast cancer?
|
Anticancer Res
|
2010
|
0.87
|
|
34
|
Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.
|
Ann Surg Oncol
|
2008
|
0.86
|
|
35
|
[Male breast cancer: a review].
|
Bull Cancer
|
2009
|
0.85
|
|
36
|
High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome.
|
Bone Marrow Transplant
|
1998
|
0.84
|
|
37
|
[HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
|
Bull Cancer
|
2010
|
0.84
|
|
38
|
[The use of breast cancer subtype classification to predict local and distant recurrence. A review].
|
Cancer Radiother
|
2008
|
0.84
|
|
39
|
Tu-be or not tu-be: that is the question… about serous ovarian carcinogenesis.
|
Crit Rev Oncol Hematol
|
2013
|
0.84
|
|
40
|
Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers.
|
Ann Oncol
|
2005
|
0.83
|
|
41
|
The Heregulin gene can be included in the 8p12 amplification unit in human breast cancer.
|
Genes Chromosomes Cancer
|
1994
|
0.82
|
|
42
|
The human FGF9 gene maps to chromosomal region 13q11-q12.
|
Genomics
|
1995
|
0.82
|
|
43
|
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.
|
Breast
|
2011
|
0.81
|
|
44
|
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
|
Ann Oncol
|
2017
|
0.80
|
|
45
|
[Ovarian epithelial dysplasia: myth or reality? Review].
|
Gynecol Obstet Fertil
|
2008
|
0.80
|
|
46
|
[Early detection of ovarian cancer: tomorrow? A review].
|
J Gynecol Obstet Biol Reprod (Paris)
|
2012
|
0.80
|
|
47
|
Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer.
|
Eur J Cancer
|
2009
|
0.79
|
|
48
|
Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression.
|
Anticancer Res
|
1995
|
0.79
|
|
49
|
Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution.
|
Pigment Cell Melanoma Res
|
2010
|
0.79
|
|
50
|
Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
|
Ann Oncol
|
2012
|
0.79
|
|
51
|
Intraoperative imprint cytology examination of sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patients.
|
Ann Surg Oncol
|
2010
|
0.78
|
|
52
|
Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials.
|
Int J Gen Med
|
2009
|
0.78
|
|
53
|
Malignant mullerian mixed tumor of the uterine cervix with adenoid cystic component.
|
Int J Gynecol Pathol
|
1998
|
0.78
|
|
54
|
Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy.
|
Breast Cancer Res Treat
|
1999
|
0.78
|
|
55
|
EGFR expression in colon cancer: a break in the clouds.
|
Ann Oncol
|
2006
|
0.77
|
|
56
|
Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions.
|
Histopathology
|
2008
|
0.77
|
|
57
|
[Ductal carcinoma in situ of the breast (DCIS). Histopathological features and treatment modalities: analysis of 1,289 cases].
|
Bull Cancer
|
2010
|
0.77
|
|
58
|
FGF7 protein expression in human breast carcinomas.
|
J Pathol
|
1998
|
0.77
|
|
59
|
Structural and numerical aberrations of chromosome 22 in a case of follicular variant of papillary thyroid carcinoma revealed by conventional and molecular cytogenetics.
|
Cancer Genet Cytogenet
|
2000
|
0.77
|
|
60
|
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry.
|
Ann Oncol
|
2013
|
0.77
|
|
61
|
[Trisomy 21 and cancers].
|
Morphologie
|
2012
|
0.77
|
|
62
|
[Quality challenge for immunohistochemistry: example of the ERBB-2 status in breast cancer. Group for Evaluation of Prognostic Factors in Immunohistochemistry in Breast Cancer (GEFPICS)].
|
Ann Pathol
|
1999
|
0.77
|
|
63
|
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
|
Oncol Res
|
2006
|
0.77
|
|
64
|
[Don't forget fallopian tubes! A morphologic and immunohistochemical study about Fallopian tubes with genetic risk (BRCA mutation)].
|
Gynecol Obstet Fertil
|
2011
|
0.76
|
|
65
|
Clinicopathological factors and nomograms predicting nonsentinel lymph node metastases after neoadjuvant chemotherapy in breast cancer patients.
|
Ann Surg Oncol
|
2009
|
0.75
|
|
66
|
[In situ mammary duct carcinoma with microinvasion. Which axillary lymph node exploration?].
|
Presse Med
|
2005
|
0.75
|
|
67
|
[Ovarian carcinogenesis: recent and past hypotheses].
|
Gynecol Obstet Fertil
|
2011
|
0.75
|
|
68
|
Correlation between molecular metastases in sentinel lymph nodes of breast cancer patients and St Gallen risk category.
|
Eur J Surg Oncol
|
2006
|
0.75
|
|
69
|
[Microinvasive ductal carcinoma of the breast. Role of axillary lymph node dissection].
|
J Gynecol Obstet Biol Reprod (Paris)
|
1999
|
0.75
|
|
70
|
Pathology of sporadic breast tumors with LOH at the BRCA1 locus: correlation with histopathological features specific to familial BRCA1 tumors and absence of microsatellite instability.
|
Int J Oncol
|
1998
|
0.75
|
|
71
|
Autologous fibroblasts as potential vehicle for regional ovarian cancer gene therapy.
|
Adv Exp Med Biol
|
1998
|
0.75
|
|
72
|
New cytogenetic data on bladder carcinoma cell line (CHA89) revealed by M-FISH analysis.
|
Cancer Genet Cytogenet
|
2000
|
0.75
|
|
73
|
[Intraoperative determination of axillary node metastasis by RT-PCR].
|
Bull Cancer
|
2010
|
0.75
|
|
74
|
Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy.
|
Cancer Gene Ther
|
2000
|
0.75
|
|
75
|
[Juxtacortical chondrosarcoma. A entity to be differentiated from periosteal osteosarcoma].
|
Ann Pathol
|
1997
|
0.75
|
|
76
|
[Clear cell sarcoma of the kidney relapsing after 10 years of asymptomatic evolution].
|
Ann Pathol
|
1997
|
0.75
|
|
77
|
Low frequency of microsatellite instability in BRCA1 mutated breast tumours.
|
J Med Genet
|
2000
|
0.75
|
|
78
|
[In vitro and in vivo models developed from human prostatic cancer].
|
Prog Urol
|
1997
|
0.75
|
|
79
|
[Molecular typing of tumors: possibilities and problems].
|
Bull Cancer
|
1997
|
0.75
|
|
80
|
[Uterine sarcoma in patients receiving tamoxifen therapy. Apropos of 2 cases].
|
Rev Med Interne
|
2001
|
0.75
|
|
81
|
[Natural history of ovarian adenocarcinomas: from epidemiology to experimentation].
|
Contracept Fertil Sex
|
1998
|
0.75
|
|
82
|
[Pancreatic and duodenal somatostatinoma. Two clinico-pathologic entities].
|
Ann Pathol
|
1996
|
0.75
|
|
83
|
[Molecular abnormalities in epithelial ovarian tumors: present and future].
|
Bull Cancer
|
2001
|
0.75
|
|
84
|
Gamma-interferon gene transfer as a therapeutic strategy for ovarian cancer.
|
Adv Exp Med Biol
|
1998
|
0.75
|
|
85
|
Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers.
|
Med Oncol
|
2005
|
0.75
|
|
86
|
[Intravascular leiomyomatosis of uterine origin. a case of pseudo-metastatic cavo-cardial thrombus].
|
Presse Med
|
1999
|
0.75
|